T1	Concept 22 39	blood lymphocytes
T2	Concept 84 94	lymphocyte
T3	Concept 153 161	COVID-19
T4	Action 69 78	suggested
T5	Concept 49 68	disease progression
T6	Concept 95 105	deficiency
T7	Concept 109 119	incapacity
R1	has-property Arg1:T6 Arg2:T2	
R2	has-property Arg1:T7 Arg2:T2	
T8	Action 7 18	correlation
T9	Concept 2 6	high
R5	has-property Arg1:T9 Arg2:T8	
T10	Concept 131 149	cellular pathology
R6	in-context Arg1:T10 Arg2:T3	
R7	causes Arg1:T2 Arg2:T10	
R8	subject Arg1:T4 Arg2:T8	
R9	target Arg1:T4 Arg2:T10	
R10	target Arg1:T8 Arg2:T1	
R3	target Arg1:T8 Arg2:T5	
T11	Action 197 209	relationship
T12	Concept 222 230	severity
T13	Concept 234 242	COVID-19
R4	in-context Arg1:T12 Arg2:T13	
T14	Concept 261 278	life satisfaction
R11	target Arg1:T11 Arg2:T12	
R12	target Arg1:T11 Arg2:T14	
T15	Concept 303 320	level of exercise
T16	Concept 291 301	ndividuals
R13	has-property Arg1:T16 Arg2:T15	
R14	causes Arg1:T15 Arg2:T11	
T17	Concept 417 439	clinical manifestation
T18	Concept 451 471	respiratory symptoms
T19	Concept 473 480	myalgia
T20	Concept 485 492	fatigue
R15	is-a Arg1:T17 Arg2:T18	
R16	is-a Arg1:T17 Arg2:T19	
R17	is-a Arg1:T17 Arg2:T20	
T21	Concept 526 534	lockdown
T22	Action 539 548	effective
T23	Action 552 561	reduction
T24	Concept 578 593	confirmed cases
T25	Concept 599 607	COVID-19
R18	in-context Arg1:T24 Arg2:T25	
R19	subject Arg1:T22 Arg2:T21	
R20	target Arg1:T22 Arg2:T23	
R21	target Arg1:T23 Arg2:T24	
T26	Concept 608 627	after about 11 days
R22	in-time Arg1:T23 Arg2:T26	
T27	Concept 631 636	china
R23	in-place Arg1:T23 Arg2:T27	
T28	Concept 674 691	incubation period
T29	Concept 695 703	COVID-19
R24	in-context Arg1:T28 Arg2:T29	
T31	Action 748 754	spread
R25	in-context Arg1:T31 Arg2:T29	
T30	Concept 376 384	COVID-19
R26	causes Arg1:T28 Arg2:T31	
